BR112022015177A2 - Uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona no tratamento inalatório de doenças pulmonares inflamatórias - Google Patents
Uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona no tratamento inalatório de doenças pulmonares inflamatóriasInfo
- Publication number
- BR112022015177A2 BR112022015177A2 BR112022015177A BR112022015177A BR112022015177A2 BR 112022015177 A2 BR112022015177 A2 BR 112022015177A2 BR 112022015177 A BR112022015177 A BR 112022015177A BR 112022015177 A BR112022015177 A BR 112022015177A BR 112022015177 A2 BR112022015177 A2 BR 112022015177A2
- Authority
- BR
- Brazil
- Prior art keywords
- dihydro
- amino
- lung diseases
- inflammatory lung
- phthalazinedione
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
USO DE 5-AMINO-2,3-DIHIDRO-1,4-FTALAZINADIONA NO TRATAMENTO INALATÓRIO DE DOENÇAS PULMONARES INFLAMATÓRIAS. A presente invenção refere-se ao uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona ou seus sais farmacêuticamente aceitáveis no tratamento inalatório de doenças pulmonares inflamatórias. A invenção em particular refere-se ao uso do sal de sódio de 5-amino-2,3-dihidro-1,4-ftalazinadiona para tais fins. As características vantajosas de um aerossol contendo 5-amino-2,3-dihidro-1,4-ftalazinadiona ou seus sais farmacêuticamente aceitáveis e um método para a produção do referido aerossol são reveladas. A presente invenção refere-se ainda a um kit para o tratamento inalatório de doenças pulmonares inflamatórias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20000051.1A EP3858328A1 (en) | 2020-01-31 | 2020-01-31 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases |
| PCT/EP2021/000009 WO2021151619A1 (en) | 2020-01-31 | 2021-01-29 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015177A2 true BR112022015177A2 (pt) | 2022-10-11 |
Family
ID=69467311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015177A BR112022015177A2 (pt) | 2020-01-31 | 2021-01-29 | Uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona no tratamento inalatório de doenças pulmonares inflamatórias |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230061223A1 (pt) |
| EP (2) | EP3858328A1 (pt) |
| JP (1) | JP2023514074A (pt) |
| KR (1) | KR20220137051A (pt) |
| CN (1) | CN115190793A (pt) |
| AU (1) | AU2021212627A1 (pt) |
| BR (1) | BR112022015177A2 (pt) |
| CA (1) | CA3162693A1 (pt) |
| IL (1) | IL294182A (pt) |
| MX (1) | MX2022009420A (pt) |
| TW (1) | TW202140013A (pt) |
| WO (1) | WO2021151619A1 (pt) |
| ZA (1) | ZA202208033B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4209219A1 (en) * | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione |
| CN114053229B (zh) * | 2022-01-17 | 2022-04-22 | 山东国邦药业有限公司 | 一种盐酸沙拉沙星水溶性颗粒剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953799B1 (en) | 2002-10-30 | 2005-10-11 | Bach Pharma, Inc. | Modulation of cell fates and activities by diketo phthalazines |
| US7326690B2 (en) | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
| RU2266119C2 (ru) * | 2003-10-21 | 2005-12-20 | Общество с ограниченной ответственностью "Абидофарма" | Препарат для ингаляций при лечении туберкулеза |
| PL231885B1 (pl) | 2009-01-16 | 2019-04-30 | Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
| JP6061081B2 (ja) | 2010-03-01 | 2017-01-18 | メトリオファーム アーゲー | ５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉまたはｉｉ、それを含有する医薬品調製物、５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉの製造方法、および５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉｉの製造方法 |
| CA2813750A1 (en) * | 2010-10-12 | 2012-04-19 | Inspire Pharmaceuticals, Inc. | Method for treating cystic fibrosis with inhaled denufosol |
| US9464079B2 (en) | 2011-03-23 | 2016-10-11 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| AP2015008556A0 (en) * | 2012-12-17 | 2015-06-30 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful forthe treatment of diseases favoured by insufficien t mucosal hydration |
| EP3233807B1 (de) | 2014-12-18 | 2019-09-04 | MetrioPharm AG | Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
| CA3011767C (en) * | 2016-02-16 | 2024-02-06 | Metriopharm Ag | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
| EP3248602A1 (en) | 2016-05-26 | 2017-11-29 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae |
| DK3534904T3 (da) | 2016-11-07 | 2022-04-11 | Metriopharm Ag | Anvendelse af 5-amino-2,3-dihydro-1,4-phthalazindion i behandlingen af kronisk progressiv multipel sklerose |
-
2020
- 2020-01-31 EP EP20000051.1A patent/EP3858328A1/en active Pending
-
2021
- 2021-01-29 EP EP21705878.3A patent/EP4096628B1/en active Active
- 2021-01-29 AU AU2021212627A patent/AU2021212627A1/en active Pending
- 2021-01-29 JP JP2022544841A patent/JP2023514074A/ja active Pending
- 2021-01-29 KR KR1020227030157A patent/KR20220137051A/ko unknown
- 2021-01-29 CA CA3162693A patent/CA3162693A1/en active Pending
- 2021-01-29 WO PCT/EP2021/000009 patent/WO2021151619A1/en unknown
- 2021-01-29 TW TW110103545A patent/TW202140013A/zh unknown
- 2021-01-29 CN CN202180011570.9A patent/CN115190793A/zh active Pending
- 2021-01-29 US US17/795,360 patent/US20230061223A1/en active Pending
- 2021-01-29 MX MX2022009420A patent/MX2022009420A/es unknown
- 2021-01-29 BR BR112022015177A patent/BR112022015177A2/pt unknown
- 2021-01-29 IL IL294182A patent/IL294182A/en unknown
-
2022
- 2022-07-19 ZA ZA2022/08033A patent/ZA202208033B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021212627A1 (en) | 2022-07-14 |
| ZA202208033B (en) | 2023-12-20 |
| CA3162693A1 (en) | 2021-08-05 |
| US20230061223A1 (en) | 2023-03-02 |
| CN115190793A (zh) | 2022-10-14 |
| IL294182A (en) | 2022-08-01 |
| WO2021151619A1 (en) | 2021-08-05 |
| TW202140013A (zh) | 2021-11-01 |
| KR20220137051A (ko) | 2022-10-11 |
| EP4096628B1 (en) | 2024-01-24 |
| JP2023514074A (ja) | 2023-04-05 |
| EP3858328A1 (en) | 2021-08-04 |
| MX2022009420A (es) | 2022-08-25 |
| EP4096628A1 (en) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015177A2 (pt) | Uso de 5-amino-2,3-dihidro-1,4-ftalazinadiona no tratamento inalatório de doenças pulmonares inflamatórias | |
| Cochran et al. | Studies on the antiviral activity of amantadine hydrochloride | |
| CY1118137T1 (el) | Αερολυμενες φθοροκινολονες και χρησεις αυτων | |
| BRPI1014783A2 (pt) | formulações farmacêuticas e métodos para tratar infecções do trato respiratório | |
| HN1999000183A (es) | Preparado farmaceuticos de moxifloxacina | |
| BRPI0513717A (pt) | derivados de piridina | |
| MX2010004673A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos. | |
| HRP20050786B1 (hr) | Lokalna primjena fluorokinolina u lijeäśenju bakterijskih oboljenja dišnih organa | |
| BRPI0707904A8 (pt) | Disfarce gustativo de fluoroquinolonas aerossolizadas | |
| BRPI0514691A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| CY1117962T1 (el) | Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης | |
| NO20064599L (no) | Substituerte morfolin- og tiomorfolinderivater | |
| UY26269A1 (es) | Formulación de sal común y moxifloxacina | |
| CY1116076T1 (el) | Νεα μεθοδος για την παρασκευη σκοπινεστερων | |
| BR112022019141A2 (pt) | 5-amino-2,3-dihidro-1,4-ftalazinadiona para tratamento de lesão pulmonar aguda | |
| BR112021023054A2 (pt) | Formas cristalinas de um inibidor de btk | |
| CL2013003057A1 (es) | Composicion farmaceutica de aerosol en forma de solución acuosa para nebulización que comprende iloprost, que proporciona una dosis unica eficaz aerolizada para inhalacion de bolo en un periodo de menos de 2 minutos; kit farmacéutio, util en el tratamiento de hipertension arterial pulmonar. | |
| BR112022019519A2 (pt) | Tratamento | |
| JP2017527618A5 (pt) | ||
| BRPI0414780B8 (pt) | composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto | |
| MX2021009796A (es) | Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5). | |
| BR112021016277A2 (pt) | Preparações para a prevenção de doenças adquiridas por meio da cavidade oral e da faringe | |
| MX2021002042A (es) | Inhibidores de arginasa y sus metodos de uso. | |
| WO2021243183A8 (en) | Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis | |
| CN111450251B (zh) | Mthfd1抑制剂在抑制和杀灭病毒中的应用 |